MARKET

DNTH

DNTH

Dianthus Therapeutics Inc
NASDAQ
81.13
-1.32
-1.60%
After Hours: 80.67 -0.46 -0.57% 18:21 03/27 EDT
OPEN
81.92
PREV CLOSE
82.45
HIGH
84.55
LOW
80.35
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
88.02
52 WEEK LOW
13.37
MARKET CAP
4.10B
P/E (TTM)
-19.2997
1D
5D
1M
3M
1Y
5Y
1D
Dianthus Therapeutics (DNTH) Receives a Buy from Wells Fargo
TipRanks · 21h ago
Dianthus Therapeutics; Director Paula Soteropoulos drops 27,594 common shares worth $2,153,736
Reuters · 1d ago
Dianthus rises as FDA agrees with proposed changes to lead program
Seeking Alpha · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Cardiff Oncology (CRDF)
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Dianthus Therapeutics (DNTH), Equillium (EQ)
TipRanks · 1d ago
Dianthus Highlights Strong Cash Runway and Streamlined Trials
TipRanks · 1d ago
DIANTHUS THERAPEUTICS- PROPOSED CHANGES TO SCREENING CRITERIA RELATED TO CLASEPRUBART TRIALS TO FDA IN Q1 2026 - SEC FILING
Reuters · 1d ago
DIANTHUS THERAPEUTICS INC - FDA AGREES TO ALL THREE PROPOSALS FOR CLASEPRUBART TRIALS IN MARCH 2026 - SEC FILING
Reuters · 1d ago
More
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Webull offers Dianthus Therapeutics Inc stock information, including NASDAQ: DNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNTH stock methods without spending real money on the virtual paper trading platform.